These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 24628303)

  • 1. Lansoprazole enhances the antidiabetic effect of sitagliptin in mice with diet-induced obesity and healthy human subjects.
    Hao S; Sun J; Tian X; Sun X; Zhang Z; Gao Y
    J Pharm Pharmacol; 2014 Aug; 66(8):1133-9. PubMed ID: 24628303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
    Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
    Souza-Mello V; Gregório BM; Cardoso-de-Lemos FS; de Carvalho L; Aguila MB; Mandarim-de-Lacerda CA
    Clin Sci (Lond); 2010 Jun; 119(6):239-50. PubMed ID: 20415664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.
    Shang Q; Liu MK; Saumoy M; Holst JJ; Salen G; Xu G
    Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G815-23. PubMed ID: 22281473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
    Herman GA; Bergman A; Liu F; Stevens C; Wang AQ; Zeng W; Chen L; Snyder K; Hilliard D; Tanen M; Tanaka W; Meehan AG; Lasseter K; Dilzer S; Blum R; Wagner JA
    J Clin Pharmacol; 2006 Aug; 46(8):876-86. PubMed ID: 16855072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.
    Yeom JA; Kim ES; Park HS; Ham DS; Sun C; Kim JW; Cho JH; Yoon KH
    BMB Rep; 2011 Nov; 44(11):713-8. PubMed ID: 22118536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
    Matthes J; Faust M
    Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
    [No Abstract]   [Full Text] [Related]  

  • 8. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice.
    Lee EY; Kim YW; Oh H; Choi CS; Ahn JH; Lee BW; Kang ES; Cha BS; Lee HC
    Metabolism; 2014 Jun; 63(6):793-9. PubMed ID: 24684824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
    Smith GC; Vickers MH; Cognard E; Shepherd PR
    Schizophr Res; 2009 Nov; 115(1):30-40. PubMed ID: 19679451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
    Alba M; Ahrén B; Inzucchi SE; Guan Y; Mallick M; Xu L; O'Neill EA; Williams-Herman DE; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1101-10. PubMed ID: 23782502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice.
    Al-Barazanji K; McNulty J; Binz J; Generaux C; Benson W; Young A; Chen L
    J Pharmacol Exp Ther; 2015 Jun; 353(3):496-504. PubMed ID: 25770135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
    Wu T; Ma J; Bound MJ; Checklin H; Deacon CF; Jones KL; Horowitz M; Rayner CK
    Diabetes; 2014 Aug; 63(8):2776-87. PubMed ID: 24647737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.
    Vardarli I; Arndt E; Deacon CF; Holst JJ; Nauck MA
    Diabetes; 2014 Feb; 63(2):663-74. PubMed ID: 24186866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ; Green BD; Flatt PR
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.